entity

SCFAs

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SCFAs: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

6Connections
4Hypotheses
6Analyses
4Outgoing
2Incoming
0Experiments
9Debates

No AI portrait yet

Outgoing (4)

TargetRelationTypeStr
alpha-synuclein aggregationinhibitsprocess0.80
neuroinflammationinhibitsprocess0.80
Neuroinflammationmodulatesprocess0.70
neuroinflammationmodulatesmechanism0.70

Incoming (2)

SourceRelationTypeStr
38565643regulatepaper0.90
38565643have been implicated inpaper0.60

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Physiological SCFAs may confer indirect anti-synuclein benef 0.670 neurodegeneration Do physiological concentrations of SCFAs
Physiological SCFAs may reduce alpha-synuclein burden primar 0.650 neurodegeneration Do physiological concentrations of SCFAs
The most realistic translational use of physiological SCFAs 0.610 neurodegeneration Do physiological concentrations of SCFAs
Physiological SCFAs may worsen alpha-synuclein pathology thr 0.550 neurodegeneration Do physiological concentrations of SCFAs

Mentioning Analyses (6)

Scientific analyses that reference this entity

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.728

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

neurodegeneration | 2026-04-26 | 3 hypotheses Top: 0.346

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.703

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically re

neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.682

What brain concentrations of SCFAs are achieved via oral probiotics and are they

pharmacokinetics | 2026-04-11 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (9)

Multi-agent debates referencing this entity

Debate: SCFA Deficiency Drives Microglial Hyperactivation via GPR43/NF-κB Dysreg

closed · Rounds: 4 · Score: 0.13 · 2026-04-27

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

closed · Rounds: 4 · Score: 0.76 · 2026-04-26

Formal debate: TLR4 priming is the actionable driver in: How does gut microbiome

closed · Rounds: 3 · Score: 0.75 · 2026-04-26

Formal debate: plasma LPS-binding protein separates causal from compensatory sta

closed · Rounds: 3 · Score: 0.75 · 2026-04-26

How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen

closed · Rounds: 4 · Score: 0.78 · 2026-04-26

The debate highlighted that while SCFAs can cross the blood-brain barrier, the a

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

How do gut microbiome-derived metabolites SCFAs LPS TMAO influence alpha-synucle

closed · Rounds: 4 · Score: 0.84 · 2026-04-16

The debate identified a critical mechanistic gap between SCFA production by gut

closed · Rounds: 4 · Score: 0.70 · 2026-04-12

What are the mechanisms underlying what are the mechanisms by which gut microbio

closed · Rounds: 4 · Score: 0.95 · 2026-04-01

Related Research

Hypotheses and analyses mentioning SCFAs in their description or question text

No additional research found